| Literature DB >> 23239936 |
Agnieszka Maria Jastrzębska1, Patrycja Kurtycz, Andrzej Roman Olszyna.
Abstract
Recently, graphene family materials (GFMs) have been introduced among all fields of science and still get numerous attention. Also, the applicability of these materials in many areas makes them very attractive. GFMs have attracted both academic and industrial interest as they can produce a dramatic improvement in materials properties at very low filler content. This article presents recent findings on GFMs toxicity properties based on the most current literature. This article studies the effects of GFMs on bacteria, mammalian cells, animals, and plants. This article also reviews in vitro and in vivo test results as well as potential anticancer activity and toxicity mechanisms of GFMs. The effect of functionalization of graphene on pacifying its strong interactions with cells and associated toxic effects was also analyzed. The authors of the article believe that further work should focus on in vitro and in vivo studies on possible interactions between GFMs and different living systems. Further research should also focus on decreasing GFMs toxicity, which still poses a great challenge for in vivo biomedical applications. Consequently, the potential impact of graphene and its derivatives on humans and environmental health is a matter of academic interest. However, potential hazards sufficient for risk assessment first need to be investigated.Entities:
Year: 2012 PMID: 23239936 PMCID: PMC3517804 DOI: 10.1007/s11051-012-1320-8
Source DB: PubMed Journal: J Nanopart Res ISSN: 1388-0764 Impact factor: 2.253
Fig. 1The members of the graphene family materials: few-layered graphene (a), graphene nanosheet (b), graphene oxide (c), and reduced graphene (d)
Summary of the graphene family materials toxicity toward bacteria species
| Original GFM name | Bacterially-reduced graphene oxide sheets | Graphene oxide sheets | Reduced graphene oxide | Graphene oxide | Graphite oxide | Graphite | Graphene |
|---|---|---|---|---|---|---|---|
| Properties (measurement method) | No data | ~1 nm TH, multi-layered, smooth planar structure (AFM) | 2.75 ± 1.18 μm LD (SEM) | 1 nm TH, single-layered (AFM) 0.31 ± 0.20 μm LD (SEM) | 6.28 ± 2.50 μm LD (SEM) | 6.87 ± 3.12 μm LD (SEM) | No data |
| Surface modifications | No modifications | No modifications | No modifications | No modifications | No modifications | No modifications | No modifications |
| Method of synthesis | Graphene oxide reduction by | Natural graphite powder oxidization by modified Hummers method | Graphene oxide reduction by hydrazine | Graphite oxide powder bath sonication in water at 550 W for 6 h | Graphite powder oxidization by modified Hummers method | Graphite powder sonication in isotonic saline solution using a bath sonicator | Graphene oxide reduction by |
| Investigated bacteria |
|
|
|
|
|
|
|
| Toxicity investigations results (measurement method) | Slight toxicity (spread plate method and metabolic activity ATP test) | No toxicity (spread plate method and metabolic activity ATP test) | ~45.9 % viability loss (spread plate method) | ~69.3 % viability loss (spread plate method) | ~15.0 % viability loss (spread plate method) | ~26.1 % viability loss (spread plate method) | No toxicity (Spectrophotometry) |
| Toxicity mechanism (measurement method) | Inhibition of cells proliferation (XPS) | Acted as biocompatible sites for adsorption and proliferation of cells (XPS) | Loss of cells integrity, cells were individually wrapped by nanosheets (SEM) 94.2 ± 1.1 % glutathione loss (glutathione oxidation assay) ROS-independent oxidative stress (XTT assay) | Loss of cells integrity, cells were individually wrapped by nanosheets (SEM) 22.2 ± 0.7 % glutathione loss (glutathione oxidation assay) ROS-independent oxidative stress (XTT assay) | 21.4 ± 1.1 % glutathione loss (glutathione oxidation assay) ROS-independent oxidative stress (XTT assay) | 29.9 ± 0.7 % glutathione loss (glutathione oxidation assay) ROS-independent oxidative stress (XTT assay) | No toxicity |
| Reference | (Akhavan and Ghaderia | (Akhavan and Ghaderia | (Liu et al. | (Liu et al. | (Liu et al. | (Liu et al. | (Wang et al. |
LD lateral dimensions, TH thickness, XTT 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, ATP adenosine triphosphate, ROS reactive oxygen species, SEM scanning electron microscope, TEM transmission electron microscope, AFM atomic force microscope, XPS X-ray photoelectron spectroscope
Summary of the graphene family materials in vitro toxicity
| Original GFM name | Layered graphene nanoplatelets | Graphene oxide films | Reduced nanographene oxide sheets | Nanographene oxide sheets | Graphene | Graphene oxide | Graphene | Graphene oxide | Multi-function magnetic graphene |
|---|---|---|---|---|---|---|---|---|---|
| Properties (measurement method) | 5.64 ± 4.56 μm LD, 1–10 layered (SEM) ~100 m2 g−1 surface area, ~2 g cm−3 density (specification sheet) | No data | 5–100 nm LD (AFM) | ~5 μm LD (AFM) | 3.018 ± 36 nm hydrodynamic diameter, −37.2 ± 1.6 mV zeta potential (Zetasizer) | Tens of nm TH , 10 μm LD (AFM) 765 ± 19 nm hydrodynamic diameter, −40.6 ± 2.9 mV zeta potential (Zetasizer) | 3.018 ± 36 nm hydrodynamic diameter, −37.2 ± 1.6 mV zeta potential (Zetasizer) | Tens of nm TH, 10 μm LD (AFM) 765 ± 19 nm hydrodynamic diameter, −40.6 ± 2.9 mV zeta potential (Zetasizer) | ~4–6 nm TH, 40–60 nm LD (AFM) |
| Surface modifications | No modifications | No modifications | Functionalized noncovalently by PEG | No modifications | No modifications | No modifications | No modifications | No modifications | 1.5 ml PAA and FMA-coated 50 mg of magnetic graphene |
| Method of synthesis | Purchased in Cheaptubes.com | Sterile PVDF paper filters were coated with graphene oxide suspensions (75 μg per filter) | Graphene oxide was added with 1,000 mg l−1 of the C18-PMH-mPEG5000 polymer and chemically reduced by hydrazine | Graphite oxidization by modified Hummers method | Graphene oxide reduction by a simple hydrazine-free hydrothermal route | Graphite oxidization by modified Hummers method | Graphene oxide reduction by a simple hydrazine-free hydrothermal route | Graphite oxidization by modified Hummers method | Magnetic graphene was synthesized by in-situ microwave-assisted reduction and magnetization process. Then, magnetic graphene was covalently modified with PAA and FMA via sonication followed by microwave irradiation method |
| Investigated cell culture line | Immortalized human monocytic cell line THP-1 | Mammalian colorectal adenocarcinoma HT-29 cells | MCF7 human epithelial breast cancer cells | MCF7 human epithelial breast cancer cells | Human skin fibroblast cells (CRL-2522) | Human skin fibroblast cells (CRL-2522) | Red blood cells obtained from human whole blood samples stabilized EDTA | Red blood cells obtained from human whole blood samples stabilized EDTA | Human cervical cancer (HeLa) cells |
| Toxicity investigations results (measurement method) | Graphene nanoplatelets was not fully phagocytosed by THP-1 cells, frustrated phagocytosis occurred (SEM) LDH release was significantly increased at >5 μg cm−2 (LDH membrane integrity assay) | Graphene oxide promotes mammalian cell attachment and proliferation (cell attachment assessment by light microscopy) | >50 % decrease in metabolic activity at 80.28 ± 17.28 mg l−1 (MTS viability assay) | >50 % decrease in metabolic activity at 99.62 ± 17.08 mg l−1 (MTS viability assay) | Only few % decrease in metabolic activity 200 μg ml−1 (MTT viability assay) >80 % decrease in metabolic activity 200 μg ml−1 (WST-8 viability assay) | Only few % decrease in metabolic activity 200 μg ml−1 (MTT viability assay) >20 % decrease in metabolic activity 200 μg ml−1 (WST-8 viability assay) | 50 % of the blood cells were hemolysed at >200 μg ml−1 (hemolysis assay) | 50 % of the blood cells were hemolysed at 142 μg ml−1 (hemolysis assay) | <60 % decrease in metabolic activity at 200 μg ml−1 (MTT viability assay) ~225 % LDH release at 200 μg ml−1 (LDH membrane integrity assay) |
| Toxicity mechanism (measurement method) | Loss of membrane integrity could be due to generation of ROS (TEM) | No data | No data | No data | Concentration-dependent generation of ROS in cells (ROS assay) | Concentration-dependent generation of ROS in cells (ROS assay) | No data | No data | Low ROS generation and cell apoptosis. Excellent co-localization in the cytoplasmic region without any surface agonist (ROS assay) |
| Reference | (Schinwald et al. | (Ruiz et al. | (Robinson et al. | (Robinson et al. | (Liao et al. | (Liao et al. | (Liao et al. | (Liao et al. | (Gollavelli and Ling |
LD lateral dimensions, TH thickness, TEM transmission electron microscope, AFM atomic force microscope, XRD X-ray diffraction, CCK-8 cell counting kit-8, LDH lactase dehydrogenase, DCFH-DA 2′,7′-dichlorofluorescin diacetate, FITC fluorescein isothiocyanate, ROS reactive oxygen species, MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, WST water-soluble tetrazolium salt, FBS fetal bovine serum, GAP-43 growth associate protein-43, PLL poly-l-lysine which is commonly used to promote cell adhesion and proliferation, PAA polylactic acid, FMA fluorescein o-methacrylate, PEG polyethylene glycol
Summary of the graphene family materials in vivo toxicity
| Original GFM name | Graphite nanoplatelets | Multi-function magnetic graphene | Graphene oxide | Graphene | Graphene | Graphene oxide | Graphene oxide |
|---|---|---|---|---|---|---|---|
| Properties (measurement method) | 1–20 nm TH, from 1–10 of μm LD, 3–60 layered (SEM) | ~4–6 nm TH, 40–60 nm LD (AFM) | 0.5–2.0 nm TH (AFM) | 1.2–5.0 nm TH (AFM) | 1.2–5.0 nm TH (AFM) | ~1 nm TH, 10–800 nm LD, single-layered (AFM) | ~1 nm TH, few μm LD, single-layered, flat and smooth sheets (TEM, AFM) |
| Surface modifications | No modifications | 1.5 ml PAA and FMA-coated 50 mg of magnetic graphene | No modifications | Graphene was dispersed by 2 % Pluronic (block copolymer) | No modifications | Radiolabeled with 188Re | No modifications |
| Method of synthesis | No data | Magnetic graphene was synthesized by in-situ microwave-assisted reduction and magnetization process. Then, magnetic graphene was covalently modified with PAA and FMA via sonication followed by microwave irradiation method microwave-heated sonication-assisted process | Natural graphite oxidization by modified Hummers method | Ultrasonication of natural graphite flakes | Ultrasonication of natural graphite flakes | Graphite powder oxidization by modified Hummers method | Natural graphite powder oxidization by modified Hummers method |
| Investigated animal (injection pathway) |
| Wild-type AB strains of | C57BL/6 mice, male, 20–25 g, 8–12 weeks old (50 μg/mouse intratracheal injection pathway—direct administration into lungs) | C57BL/6 mice, male, 20–25 g, 8–12 weeks old (50 μg/mouse intratracheal injection pathway—direct administration into lungs) | C57BL/6 mice, male, 20–25 g, 8–12 weeks old (50 μg/mouse intratracheal injection pathway—direct administration into lungs) | Kun Ming mice, male, 20 ± 2 g, 6–8 weeks old (intravenous injection pathway) | Kun Ming mice, female, 28–30 g, 4–5 weeks old (intravenous injection pathway) |
| Toxicity investigations results (measurement method) | No acute or chronic toxicity (longevity measurement) No effect on reproductivity (reproductivity assessment) | No influence on survival rate | Lung injury, severe inflammation with alveolar exudates, hyaline membrane formation, leakage of protein into the alveolar space (low power electron micrography) | Homogeneous distribution in lungs, minimal histologic evidence of lung inflammation (low power electron micrography) | Nonhomogeneous distribution in lungs, minimal histologic evidence of lung inflammation (low power electron micrography) | No data on mortality because all mice were artificially sacrificed after graphene oxide injection | No mortality with <0,25 mg dose, 50 % mortality with 0.4 mg dose (mortality assessment after 1–7 days) |
| Toxicity mechanism (measurement method) | Good distribution along the whole body, transition from the intestine to the gonads (FT-IR mapping) | Biocompatible, good distribution from the head to tail (whole-animal microscopic imaging) | No data | No data | No data | Cell infiltration and significant pathological changes: inflammation, pulmonary edema, granuloma formation in the lung when exposed to 10 mg kg−1 body weight for 14 days (gamma-ray radioactivity counter) | Accumulation and high granuloma formation in lungs, liver, kidney, and spleen. No brain accumulation due to blood–brain barrier (organs histopathology and light micrography) |
| Reference | (Zanni et al. | (Gollavelli and Ling | (Duch et al. | (Duch et al. | (Duch et al. | (Zhang et al. | (Wang et al. |
LD lateral dimensions, TH thickness, TEM transmission electron microscope, SEM scanning electron microscope, AFM atomic force microscope, PAA polylactic acid, FMA fluorescein o-methacrylate, FT-IR fourier-transform infrared spectroscopy
Fig. 2The schematic summary of the toxicological aspects of graphene family materials in relation to their synthesis techniques
Fig. 3The schematic summary of the toxicological aspects of graphene oxide in relation to its synthesis techniques and chosen properties such as: thickness (TH) and lateral dimensions (LD)